A report demonstrates that the Incidence rates for malignant brain and other central nervous system tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined.
A phase II trial led by City of Hope suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.
A perspective article by researchers at Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer.
FDA issued a safety communication Aug. 20 that included new recommendations for IRBs and investigators studying robotically-assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of breast cancer.
Genentech has withdrawn the U.S. accelerated approval indication for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDA)-approved test.
Tibsovo (ivosidenib) has received FDA approval for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Opdivo (nivolumab) has received FDA approval (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection.
Jemperli (dostarlimab-gxly) has received accelerated approval from FDA for adult patients with mismatch repair deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, has received FDA approval for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
Keytruda plus Lenvima have received FDA approval as first-line treatment of adult patients with advanced renal cell carcinoma.
